HairDX Announces New and Improved Genetic Test for Hair Loss

The folks at HairDX, which announced last January a genetic test for identifying future hair loss or Male Pattern Baldness, announced a new and improved version that builds on recent genetic discoveries.

According to the company, using the HairDX test a physician can tell a man who tests positive for the high risk genetic variant that he has approximately a 70% chance of going bald. Similarly, a physician can tell a man who tests negative for the high risk genetic variant that he has approximately a 70% chance of not going bald. The HairDX test is available immediately through qualified physicians’ offices.

HairDX is a subsidiary of PharmaGenoma, Inc., a “pharmacogenomics research and development innovator.”

“The next generation test report is based on a pooled data model from multiple peer reviewed studies of over 2,000 Caucasian men,” said Andy Goren, HairDX Chairman and Co-Founder. “The studies demonstrated the association between the genetic variants measured by the HairDX genetic screening test and the development of Androgenetic Alopecia in men.”

In addition to the improved clinical validity and utility, the HairDX genetic test now includes genetic markers on the Androgen Receptor (AR) gene as well as on Chromosome 20.

“A recent study demonstrated that Propecia©, the only FDA approved oral prescription medication for the treatment of male pattern baldness, is effective at preventing hair loss over a period of several years,” said Dr. Sharon Keene, Chief Medical Officer for HairDX and former Chairman of the Annual Scientific Committee of the International Society of Hair Restoration Surgeons. “Doctors using the HairDX genetic screening test can offer a treatment plan to prevent hair loss in men of all ages before any visible signs of hair loss.”

So, what difference can the HairDX test make — practically speaking? According to Keene and others, visible signs of hair loss usually mean that a man has already lost up to 50% of their hair. Early detection via the HairDX genetic screening test, they say, provides an opportunity for “intervention and treatment” before it is too late.

The next generation screening test identifies approximately 70% of men that will benefit from early treatment. As with any screening test, some men will be identified for treatment even though they may not go bald. Confirmatory tests by a qualified physician will eliminate unnecessary treatment.

For more info on the test, visit HairDX’s website at http://hairdx.com.